0RU5 Bergenbio Asa

BERGEN, Norway, March 4, 2021 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has closed recruitment into the company sponsored randomised Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India.

A total of 114 out of the target 120 hospitalised COVID-19 patients have been recruited across five sites in South Africa and seven sites in India. 56 patients received bemcentinib (as monotherapy or in combination with standard of care medication) and 58 patients in a control group (receiving standard of care treatment only). The trial protocol permits co-administration with other medicines recommended for treatment of COVID-19, including remdesivir and dexamethasone. The integrity and statistical power of the data remains intact and top line clinical results are expected to read out around the end of Q1 2021.

The primary endpoint of the trial is time to clinical improvement of at least two points (from randomisation) on the WHO nine-point ordinal scale, or live discharge from the hospital, whichever comes first. Key secondary endpoints include viral load, clinical markers of disease progression and survival rate.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "The incidence of COVID-19 has fallen significantly in South Africa, so we have taken the decision to close the study for recruitment in a timely fashion, this allows us to analyse the data without loss of quality and maintain our momentum in the development of bemcentinib as a potential treatment for COVID-19. We aim to share initial data as soon as possible around the end of this quarter and remain hopeful that bemcentinib can play a role in treating COVID-19 patients and complement the global vaccination programmes."

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters the host cell, and AXL expression is upregulated that leads to suppression of the Type 1 Interferon immune response by host cells and in their environment. Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and suppresses anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers. AXL suppresses the body's immune response to tumours and drives treatment failure across many cancers. High AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib, therefore, have potential high value as monotherapy and as the cornerstone of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent and highly selective AXL inhibitor, currently in a broad phase II clinical development programme. It is administered as an oral capsule and taken once per day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity.

About BerGenBio ASA 

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com 

Contacts 
Richard Godfrey CEO, BerGenBio ASA 
ir@bergenbio.com 

Rune Skeie, CFO, BerGenBio ASA 
rune.skeie@bergenbio.com 
+47 917 86 513 

International Media Relations 

Mary-Jane Elliott
Chris Welsh
Lucy Featherstone
Carina Jurs 
Consilium Strategic Communications 
bergenbio@consilium-comms.com   
+44 20 3709 5700 

Media Relations in Norway 
Jan Petter Stiff
Crux Advisers 
stiff@crux.no 
+47 995 13 891 

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bergenbio-asa/r/bergenbio-closes-recruitment-into-trial-assessing-bemcentinib-in-covid-19-patients,c3299896

The following files are available for download: